Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
Top Cited Papers
- 1 July 2007
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 370 (9581) , 49-58
- https://doi.org/10.1016/s0140-6736(07)61049-6
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsThe Lancet, 2007
- Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patientsAIDS, 2007
- Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1AIDS, 2007
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2006)HIV Medicine, 2006
- Treatment for Adult HIV InfectionJAMA, 2006
- Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresAIDS, 2005
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaNew England Journal of Medicine, 2003
- Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced PatientsThe Journal of Infectious Diseases, 2002
- The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infectionAIDS, 1998